Skip to main content

Peer Review reports

From: Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report

Original Submission
8 May 2017 Submitted Original manuscript
31 May 2017 Reviewed Reviewer Report - Adrija Hajra
2 Jun 2017 Reviewed Reviewer Report - Malik Ghannam
3 Jun 2017 Reviewed Reviewer Report - Ahmet Emre Eskazan
9 Jun 2017 Reviewed Reviewer Report - Katia ALLAL TAOULI
10 Jul 2017 Author responded Author comments - Tatsuyoshi Ikenoue
Resubmission - Version 2
10 Jul 2017 Submitted Manuscript version 2
19 Jul 2017 Reviewed Reviewer Report - Ahmet Emre Eskazan
30 Aug 2017 Author responded Author comments - Tatsuyoshi Ikenoue
Resubmission - Version 3
30 Aug 2017 Submitted Manuscript version 3
11 Sep 2017 Author responded Author comments - Tatsuyoshi Ikenoue
Resubmission - Version 4
11 Sep 2017 Submitted Manuscript version 4
Publishing
20 Sep 2017 Editorially accepted
19 Oct 2017 Article published 10.1186/s13256-017-1468-z

You can find further information about peer review here.

Back to article page